{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:56:28Z","timestamp":1786362988935,"version":"build-2736575974"},"reference-count":14,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T00:00:00Z","timestamp":1514246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.usa.gov\/government-works"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Automated treponemal immunoassays are used for syphilis screening with the reverse-sequence algorithm; discordant results (e.g., enzyme immunoassay [EIA] reactive and reactive plasma reagin [RPR] nonreactive) are resolved with a second treponemal test. We conducted a study to determine automated immunoassay signal strength values consistently correlating with reactive confirmatory treponemal testing. We conducted a cross-sectional analysis of four automated immunoassays (BioPlex 2200 microbead immunoassay [MBIA], Liaison chemiluminescence immunoassay [CIA], Advia-Centaur CIA, and Trep-Sure EIA) and three manual assays (\n            <jats:named-content content-type=\"genus-species\">Treponema pallidum<\/jats:named-content>\n            particle agglutination [TP-PA], fluorescent treponemal antibody absorption [FTA-ABS] test, and Inno-LIA line immunoassay). We compared signal strength values of automated immunoassays and positive and negative agreement. Among 1,995 specimens, 908 (45.5%) were true positives (\u22654\/7 tests reactive) and 1,087 (54.5%) were true negatives (\u22654\/7 tests nonreactive). Positive agreement ranged from 86.1% (83.7 to 88.2%) for FTA-ABS to 99.7% (99.0 to 99.9%) for Advia-Centaur CIA; negative agreement ranged from 86.3% (84.1 to 88.2%) for Trep-Sure EIA to 100% for TP-PA (99.6 to 100%). Increasing signal strength values correlated with increasing reactivity of confirmatory testing (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.0001 for all automated immunoassays by Cochran-Armitage test for trend). All automated immunoassays had signal strength cutoffs corresponding to \u22654\/7 reactive treponemal tests. BioPlex MBIA and Liaison CIA had signal strength cutoffs correlating with \u226599% and 100% TP-PA reactivity, respectively. The Advia-Centaur CIA and Trep-Sure EIA had signal strength cutoffs correlating with at least 95% TP-PA reactivity. All automated immunoassays had signal strength cutoffs correlating with at least 95% FTA-ABS reactivity. Assuming that a 95% level of confirmation is adequate, these signal strength values can be used in lieu of confirmatory testing with TP-PA and FTA-ABS.\n          <\/jats:p>","DOI":"10.1128\/jcm.01165-17","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T00:25:41Z","timestamp":1508372741000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":17,"title":["Correlation of Treponemal Immunoassay Signal Strength Values with Reactivity of Confirmatory Treponemal Testing"],"prefix":"10.1128","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-8981","authenticated-orcid":false,"given":"Yetunde F.","family":"Fakile","sequence":"first","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Jost","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen W.","family":"Hoover","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen J.","family":"Gustafson","sequence":"additional","affiliation":[{"name":"Sexually Transmitted Disease Control Branch, Division of Communicable Disease Control, Center for Infectious Diseases, California Department of Public Health, Richmond, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Novak-Weekley","sequence":"additional","affiliation":[{"name":"Southern California Permanente Medical Group Regional Reference Laboratories, North Hollywood, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff M.","family":"Schapiro","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northern California Regional Laboratory, Berkeley, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Tran","sequence":"additional","affiliation":[{"name":"San Francisco Department of Public Health, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan M.","family":"Chow","sequence":"additional","affiliation":[{"name":"Southern California Permanente Medical Group Regional Reference Laboratories, North Hollywood, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina U.","family":"Park","sequence":"additional","affiliation":[{"name":"Southern California Permanente Medical Group Regional Reference Laboratories, North Hollywood, California, USA"},{"name":"Department of Family and Community Medicine, School of Medicine, University of California\u2014San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","first-page":"133","article-title":"Discordant results from reverse sequence syphilis screening\u2014five laboratories, United States, 2006\u20132010","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. 2011. Discordant results from reverse sequence syphilis screening\u2014five laboratories, United States, 2006\u20132010. MMWR Morb Mortal Wkly Rep 60:133\u2013137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_3_3_2","first-page":"872","article-title":"Syphilis testing algorithms using treponemal tests for initial screening\u2014four laboratories, New York City, 2005\u20132006","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","unstructured":"Centers for Disease Control and Prevention. 2008. Syphilis testing algorithms using treponemal tests for initial screening\u2014four laboratories, New York City, 2005\u20132006. MMWR Morb Mortal Wkly Rep 57:872\u2013875.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6404a1"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqw182"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05335-11"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir524"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e318205491a"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05066-11"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02555-10"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000066"},{"key":"e_1_3_3_12_2","unstructured":"Centers for Disease Control and Prevention. 2015. Viral hepatitis: guidelines for laboratory testing and reporting. Centers for Disease Control and Prevention Atlanta GA. https:\/\/www.cdc.gov\/hepatitis\/hcv\/labtesting.htm. Accessed 12 February 2017."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05636-11"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000524"},{"key":"e_1_3_3_15_2","volume-title":"Fast facts about Kaiser Permanente","author":"Kaiser Permanente","unstructured":"Kaiser Permanente. Fast facts about Kaiser Permanente. Kaiser Permanante, Oakland, CA. https:\/\/share.kaiserpermanente.org\/article\/fast-facts-about-kaiser-permanente\/. Accessed 5 December 2016."}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.01165-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.01165-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T10:14:16Z","timestamp":1646475256000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.01165-17"}},"subtitle":[],"editor":[{"given":"Yi-Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1128\/JCM.01165-17"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01165-17","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"2017-07-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01165-17"}}